Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0008508
UniProt IDP10721
Primary gene name(s)KIT
Synonym gene name(s)SCFR
Protein nameMast/stem cell growth factor receptor Kit
Protein functionTyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the AKT1 signaling pathway by phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Activated KIT also transmits signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3, STAT5A and STAT5B. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. KIT signaling is modulated by protein phosphatases, and by rapid internalization and degradation of the receptor. Activated KIT promotes phosphorylation of the protein phosphatases PTPN6/SHP-1 and PTPRU, and of the transcription factors STAT1, STAT3, STAT5A and STAT5B. Promotes phosphorylation of PIK3R1, CBL, CRK, isoform Crk-II, LYN, MAPK1/ERK2 and/or MAPK3/ERK1, PLCG1, SRC and SHC1. {ECO:0000269|PubMed:10397721, ECO:0000269|PubMed:12444928, ECO:0000269|PubMed:12511554, ECO:0000269|PubMed:12878163, ECO:0000269|PubMed:17904548, ECO:0000269|PubMed:19265199, ECO:0000269|PubMed:21135090, ECO:0000269|PubMed:21640708, ECO:0000269|PubMed:7520444, ECO:0000269|PubMed:9528781}.
Subcellular locationIsoform 1: Cell membrane;
Single-pass type I membrane protein.;
SUBCELLULAR LOCATION: Isoform 2: Cell membrane;
Single-pass type I membrane protein.;
SUBCELLULAR LOCATION: Isoform 3: Cytoplasm. Note=Detected in the cytoplasm of spermatozoa, especially in the equatorial and subacrosomal region of the sperm head.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P10721
Gene Ontology
(Biological Process)
Complete annatation
actin cytoskeleton reorganization [GO:0031532];
activation of MAPK activity [GO:0000187];
cell chemotaxis [GO:0060326];
cellular response to thyroid hormone stimulus [GO:0097067];
cytokine-mediated signaling pathway [GO:0019221];
dendritic cell cytokine production [GO:0002371];
detection of mechanical stimulus involved in sensory perception of sound [GO:0050910];
digestive tract development [GO:0048565];
ectopic germ cell programmed cell death [GO:0035234];
embryonic hemopoiesis [GO:0035162];
epithelial cell proliferation [GO:0050673];
erythrocyte differentiation [GO:0030218];
erythropoietin-mediated signaling pathway [GO:0038162];
Fc receptor signaling pathway [GO:0038093];
germ cell migration [GO:0008354];
glycosphingolipid metabolic process [GO:0006687];
hematopoietic stem cell migration [GO:0035701];
hemopoiesis [GO:0030097];
immature B cell differentiation [GO:0002327];
inflammatory response [GO:0006954];
Kit signaling pathway [GO:0038109];
lamellipodium assembly [GO:0030032];
lymphoid progenitor cell differentiation [GO:0002320];
male gonad development [GO:0008584];
MAPK cascade [GO:0000165];
mast cell chemotaxis [GO:0002551];
mast cell cytokine production [GO:0032762];
mast cell degranulation [GO:0043303];
mast cell differentiation [GO:0060374];
mast cell proliferation [GO:0070662];
megakaryocyte development [GO:0035855];
melanocyte adhesion [GO:0097326];
melanocyte differentiation [GO:0030318];
melanocyte migration [GO:0097324];
myeloid progenitor cell differentiation [GO:0002318];
negative regulation of programmed cell death [GO:0043069];
ovarian follicle development [GO:0001541];
peptidyl-tyrosine phosphorylation [GO:0018108];
phosphatidylinositol-mediated signaling [GO:0048015];
pigmentation [GO:0043473];
positive regulation of cell migration [GO:0030335];
positive regulation of cell proliferation [GO:0008284];
positive regulation of gene expression [GO:0010628];
positive regulation of JAK-STAT cascade [GO:0046427];
positive regulation of long-term neuronal synaptic plasticity [GO:0048170];
positive regulation of MAPK cascade [GO:0043410];
positive regulation of Notch signaling pathway [GO:0045747];
positive regulation of phosphatidylinositol 3-kinase activity [GO:0043552];
positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068];
positive regulation of phospholipase C activity [GO:0010863];
positive regulation of pseudopodium assembly [GO:0031274];
positive regulation of sequence-specific DNA binding transcription factor activity [GO:0051091];
positive regulation of tyrosine phosphorylation of Stat1 protein [GO:0042511];
positive regulation of tyrosine phosphorylation of Stat3 protein [GO:0042517];
positive regulation of tyrosine phosphorylation of Stat5 protein [GO:0042523];
positive regulation of vascular smooth muscle cell differentiation [GO:1905065];
protein autophosphorylation [GO:0046777];
regulation of cell proliferation [GO:0042127];
regulation of cell shape [GO:0008360];
regulation of developmental pigmentation [GO:0048070];
regulation of phosphatidylinositol 3-kinase signaling [GO:0014066];
signal transduction [GO:0007165];
somatic stem cell division [GO:0048103];
somatic stem cell population maintenance [GO:0035019];
spermatid development [GO:0007286];
spermatogenesis [GO:0007283];
stem cell differentiation [GO:0048863];
stem cell population maintenance [GO:0019827];
T cell differentiation [GO:0030217];
visual learning [GO:0008542]
Gene Ontology
(Molecular Function)
Complete annatation
ATP binding [GO:0005524];
cytokine binding [GO:0019955];
metal ion binding [GO:0046872];
phosphatidylinositol-4,5-bisphosphate 3-kinase activity [GO:0046934];
protein homodimerization activity [GO:0042803];
protein tyrosine kinase activity [GO:0004713];
Ras guanyl-nucleotide exchange factor activity [GO:0005088];
receptor signaling protein tyrosine kinase activity [GO:0004716];
stem cell factor receptor activity [GO:0005020];
transmembrane receptor protein tyrosine kinase activity [GO:0004714]
Gene Ontology
(Cellular Component)
Complete annatation
acrosomal vesicle [GO:0001669];
cell-cell junction [GO:0005911];
cytoplasmic side of plasma membrane [GO:0009898];
external side of plasma membrane [GO:0009897];
extracellular space [GO:0005615];
integral component of membrane [GO:0016021];
mast cell granule [GO:0042629];
plasma membrane [GO:0005886]
Protein-protein interaction110015
Phylogenetic treeP10721
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      unknown
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3unknownunknownunknown
AZA vs. DISU-0.1057269897778470.72389308597180.974208899704183
AZA vs. IL7-0.07242133600549370.7734769963674370.999311006273513
AZA vs. SAHA-0.09039770559467230.7601195302763770.935749414029693
DISU vs. CD3unknownunknownunknown
DISU vs. IL70.02622939198488160.9293705176784640.986985597323202
DISU vs. SAHA0.01454322739703170.9649474308053590.992637214624418
DMSO vs. AZA0.09722010134558850.7459242479576181
DMSO vs. CD32.461377439264753.23699923239218e-050.000164359263350146
DMSO vs. DISU0.2049401287259310.5779490755196190.932467317571925
DMSO vs. IL7-0.1671508604050010.5984360965027710.911970258876874
DMSO vs. SAHA-0.1988646196928410.5832224515401580.857097110366549
HIV vs. Mock in Activationunknownunknownunknown
HIV vs. Mock in Latency-0.03517416210362340.9442998065234490.999834320637052
IL7 vs. CD3unknownunknownunknown
SAHA vs. CD3unknownunknownunknown
SAHA vs. IL7-0.0242631080241860.9339175928803320.975124596181902
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
-0.7095 0.0191

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.967135 0.000305467
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
unknown unknown unknown unknown unknown
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB00398 Sorafenib approved, investigational yes antagonist
DB00619 Imatinib approved yes antagonist
DB01254 Dasatinib approved, investigational unknown antagonist
DB01268 Sunitinib approved, investigational yes inhibitor
DB01962 Phosphonotyrosine experimental unknown unknown
DB04868 Nilotinib approved, investigational unknown antagonist
DB05216 MP470 investigational unknown unknown
DB05153 XL184 investigational unknown unknown
DB05146 XL820 investigational unknown unknown
DB06080 ABT-869 investigational unknown unknown
DB05913 OSI-930 investigational unknown unknown
DB06589 Pazopanib approved yes inhibitor
DB08896 Regorafenib approved yes inhibitor
DB08901 Ponatinib approved unknown inhibitor
DB09078 Lenvatinib approved yes Inhibitor

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1PKG X-ray 2.9Å A/B=549-935.
1QZJ Model - A=576-932.
1QZK Model - A=576-932.
1R01 Model - A=576-932.
1T45 X-ray 1.9Å A=547-693# A=754-935.
1T46 X-ray 1.6Å A=565-693# A=754-935.
2E9W X-ray 3.5Å A/B=26-514.
2EC8 X-ray 3.0Å A=1-519.
2IUH X-ray 2.0Å B=718-728.
2VIF X-ray 1.4Å P=564-574.
3G0E X-ray 1.6Å A=544-693# A=754-935.
3G0F X-ray 2.6Å A/B=544-693# A/B=754-935.
4HVS X-ray 1.9Å A=551-934.
4K94 X-ray 2.4Å C=308-518.
4K9E X-ray 2.7Å C=308-518.
4PGZ X-ray 2.4Å A/B/C=308-518.
4U0I X-ray 2.0Å A=563-693# A=754-935.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Tat downregulates 23898208
Nef upregulates 9108086

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa04014 Ras signaling pathway - Homo sapiens (human)
hsa04015 Rap1 signaling pathway - Homo sapiens (human)
hsa04060 Cytokine-cytokine receptor interaction - Homo sapiens (human)
hsa04072 Phospholipase D signaling pathway - Homo sapiens (human)
hsa04144 Endocytosis - Homo sapiens (human)
hsa04151 PI3K-Akt signaling pathway - Homo sapiens (human)
hsa04640 Hematopoietic cell lineage - Homo sapiens (human)
hsa04916 Melanogenesis - Homo sapiens (human)
hsa05200 Pathways in cancer - Homo sapiens (human)
hsa05221 Acute myeloid leukemia - Homo sapiens (human)
hsa05224 Breast cancer - Homo sapiens (human)
hsa05230 Central carbon metabolism in cancer - Homo sapiens (human)
Menu